Charles Schwab’s Ascendis Pharma A/S ASND Stock Holding History

Charles Schwab’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.54M	Buy	+17,014	New	+$3.97M	﹤0.01%	2523

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Charles Schwab's ASND Position: Q2 2026 in Review

Charles Schwab opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 17,014 shares worth $4.54M. The stake represents ﹤0.01% of the portfolio and ranks #2523 among its holdings.

311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Charles Schwab held 17,014 shares of Ascendis Pharma A/S worth $4.54M as of Q2 2026.
Ascendis Pharma A/S was a new Charles Schwab position in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2523 holding.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.